Research Methods Evidence Synthesis

Body composition in male hypogonadism: practical considerations to the use of dual-energy x-ray absorptiometry

Delbarba A, Amer M, Vena W, Cangiano B, Ferrante E, Pizzocaro A, Chilà A, Romeo M, Lanzi V, Buoso C, Tiecco G, Riva M, Berruti A, Mazziotti G, Ferlin A, Bonomi M

Published August 2026 Reviews in endocrine & metabolic disorders
DOI 10.1007/s11154-026-10054-5 PMID 42178471 PMC PMC13388776

RRM Academy Synopsis

Low testosterone in men lowers muscle and raises body fat

This review of published studies links low testosterone in men to less muscle and more body fat, especially belly fat. The authors cover Klinefelter syndrome, prostate cancer treatment and HIV, and explain what DXA body scans measure.

Nearly 2 in 10 men with Klinefelter syndrome had vertebral fractures
Nearly 2 in 10 men with Klinefelter syndrome had vertebral fractures. Source: Delbarba A et al., 2026, PMID 42178471.
Study at a glance, review of published studies: Low testosterone in men lowers muscle and raises body fat
Study at a glance, review of published studies: Low testosterone in men lowers muscle and raises body fat. Source: Delbarba A et al., 2026, PMID 42178471.

Key Findings

  • In men receiving androgen deprivation therapy for prostate cancer, lean body mass dropped 3.8% and fat body mass rose 11% over 12 months.
  • In a multicenter cross-sectional study of 71 men with Klinefelter syndrome (median age 41 years), 19% had vertebral fractures, which occurred independently of bone mineral density.
  • In that Klinefelter study, impaired trabecular bone score, a texture measure of bone microarchitecture, appeared in 26% of the men.
  • In intervention studies, testosterone therapy can reduce visceral and subcutaneous fat mass and waist circumference, and increase lean mass.
  • In a study of men living with HIV, sarcopenic obesity affected 11.4% by one lean-mass index and 12.4% by another.

Interpretation

This review describes published studies on body composition in male hypogonadism, including Klinefelter syndrome, androgen deprivation therapy for prostate cancer, and HIV, and explains what DXA body scans measure. In prostate cancer, the drop in lean mass and rise in fat mass followed testosterone lowered on purpose as treatment. Bone scans can also miss fracture risk in Klinefelter syndrome and in many men on androgen deprivation therapy. The authors note that DXA cutoffs for body composition still lack consensus. The findings support further research on body composition and bone health in male hypogonadism.

RRM Context

Restorative Reproductive Medicine considers both partners and seeks the cause of a problem first. The review sets low testosterone within muscle, fat and bone health. It also separates primary, congenital and functional causes.

Abstract

Male hypogonadism is associated with significant alterations in body composition, including reduced lean body mass (LBM), increased fat body mass (FBM), particularly visceral adiposity, and impaired muscle function, contributing to frailty and cardiometabolic risk. These changes reflect the disruption of a complex endocrine crosstalk among bone, muscle, and adipose tissue, mediated by cytokines such as osteokines, myokines, and adipokines. This dysregulation promotes the development of osteosarcopenic obesity, a condition characterized by the coexistence of low bone mass, sarcopenia, and excess adiposity. Testosterone (T) plays a central role in maintaining body composition by stimulating muscle protein synthesis, inhibiting adipogenesis, and preserving bone health. Its deficiency, irrespective of etiology, leads to rapid impairment of anabolic pathways, resulting in decreased lean mass and increased fat accumulation. Evidence from clinical and experimental models demonstrates that these alterations are partially reversible with T replacement therapy (TRT), although variability exists depending on the underlying cause of hypogonadism. Dual-energy X-ray absorptiometry (DXA) represents the gold standard for assessing bone mineral density (BMD) and a key tool for evaluating body composition through a three-compartment model. It allows precise quantification of fat and lean mass, as well as their regional distribution, with minimal radiation exposure. In this review, we provide a comprehensive and clinically oriented overview of body composition alterations in male hypogonadism, focusing on underlying pathophysiological mechanisms and the practical application of DXA across different clinical scenarios. We discuss evidence from conditions such as Klinefelter syndrome, Kallmann syndrome, androgen deprivation therapy, HIV infection, and transgender care, aiming to offer a pragmatic framework for integrating body composition assessment into routine practice and improving patient management.

Topics

By this author

Related research

Research Methods › Evidence Synthesis › Systematic Reviews
Andrea Delbarba, Myriam Amer, Walter Vena, Biagio Cangiano, Emanuele Ferrante, Alessandro Pizzocaro, Alessandro Chilà, Marilina Romeo, Valeria Lanzi, Caterina Buoso, Giorgio Tiecco, Matteo Riva, Alfredo Berruti, Gherardo Mazziotti, Alberto Ferlin, Marco Bonomi
A Delbarba, M Amer, W Vena, B Cangiano, E Ferrante, A Pizzocaro, A Chilà, M Romeo, V Lanzi, C Buoso, G Tiecco, M Riva, A Berruti, G Mazziotti, A Ferlin, M Bonomi
PMID 42178471 42178471 DOI 10.1007/s11154-026-10054-5 10.1007/s11154-026-10054-5 Delbarba et al. 2026, Delbarba 2026